Aegle Therapeutics Corporation announced that the FDA has granted Fast Track designation to AGLE-102™ for the treatment of patients with dystrophic epidermolysis bullosa , a rare genetic pediatric skin blistering disorder. AGLE-102 is an extracellular vesicle therapy that delivers proteins, genetic material and regenerative healing factors to diseased and damaged tissue. AGLE-102 will be evaluated in DEB patients in a phase I/IIa trial initiating in 2021. Youway is ready to support customers with Fast Track and other accelerated clinical trials.
Back to Index
6681 Snowdrift Road
Toll Free:
Fax:
Email:
